dr. chandra belani on atezolizumab in nsclc
Published 8 years ago • 184 plays • Length 1:45Download video MP4
Download video MP3
Similar videos
-
0:58
dr. chandra belani on selecting the best anti pd-l1 agent in lung cancer
-
1:29
dr. chandra p. belani on the importance of immunotherapies in treating lung cancer
-
1:18
dr. belani discusses treating nsclc with co-1686
-
1:41
dr. belani on impact of nivolumab's approval in nsclc
-
0:56
dr. belani on treating older patients with nsclc
-
1:21
dr. belani discusses nsclc adjuvant therapy
-
1:50
dr. melissa johnson on atezolizumab in patients with nsclc
-
1:08
dr. horn on the fda approval of atezolizumab plus bevacizumab and chemotherapy in nsclc
-
1:18
dr. belani on treating nsclc with nintedanib
-
1:05
dr. johan vansteenkiste on atezolizumab in nsclc
-
2:09
dr. belani on the treatment of lung cancer subgroups
-
2:15
dr. wakelee on birch trial for atezolizumab in patients with nsclc
-
2:07
dr. belani on pd-1 inhibitors for non-small cell lung cancer
-
1:41
adjuvant atezolizumab in nsclc
-
4:18
impower110: atezolizumab vs chemo in pd-l1–selected nsclc
-
1:12
dr. horn discusses next steps with atezolizumab in sclc
-
8:20
impower010: atezolizumab versus best supportive care after adjuvant chemotherapy in resected nsclc
-
0:49
should radiation be added to chemotherapy for induction treatment in lung cancer?
-
4:31
impower130: pfs and safety of adding atezolizumab to first-line nsclc therapy